$0.00
(Market cap
$76 Mln
Revenue (TTM)
$53 Mln
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-7.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
488,846,722
8 Years Aggregate
CFO
$-913.04 Mln
EBITDA
$-1,083.79 Mln
Net Profit
$-1,255.35 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gossamer Bio (GOSS)
| -94.5 | -14.4 | -21.7 | -93.1 | -44.9 | -55.7 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Gossamer Bio (GOSS)
| 242.7 | -0.9 | -57.9 | -80.8 | 17.0 | -38.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gossamer Bio (GOSS)
|
0.2 | 75.6 | 53.3 | -125.2 | -386.0 | -- | -- | 2.7 |
| 85.0 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 247.9 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 73.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.2 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 351.4 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 532.8 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 607.9 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 352.3 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Gossamer Bio (GOSS)
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an... inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California. Read more
-
Co-Founder, CEO, President & Chairman
Mr. Faheem Hasnain
-
Co-Founder, CEO, President & Chairman
Mr. Faheem Hasnain
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Gossamer Bio (GOSS)
What is the current share price of Gossamer Bio Inc (GOSS) Today?
The share price of Gossamer Bio Inc (GOSS) is $0.17 (NASDAQ) as of 28-Aug-2026 11:38 EDT. Gossamer Bio Inc (GOSS) has given a return of -44.89% in the last 3 years.
What is the current PB & PE ratio of Gossamer Bio Inc (GOSS)?
Since, TTM earnings of Gossamer Bio Inc (GOSS) is negative, P/E ratio is not available.
The P/B ratio of Gossamer Bio Inc (GOSS) is 2.66 times as on 21-Aug-2026, a 50 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.12 |
-5.72 |
2024 |
-3.63 |
6.95 |
2023 |
-1.14 |
3.28 |
2022 |
-0.89 |
16.94 |
2021 |
-3.65 |
7.04 |
What is the 52 Week High and Low of Gossamer Bio Inc (GOSS)?
The 52-week high and low of Gossamer Bio Inc (GOSS) are Rs 3.87 and Rs 0.11 as of 28-Aug-2026.
What is the market cap of Gossamer Bio Inc (GOSS)?
Gossamer Bio Inc (GOSS) has a market capitalisation of $ 76 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Gossamer Bio Inc (GOSS)?
Before investing in Gossamer Bio Inc (GOSS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.